Department of Laboratory Medicine and Genetics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
Department of Laboratory Medicine, Seoul Medical Center, Seoul, Korea.
Ann Lab Med. 2021 Mar 1;41(2):225-229. doi: 10.3343/alm.2021.41.2.225.
In response to the ongoing coronavirus disease 2019 (COVID-19) pandemic, an online laboratory surveillance system was established to monitor severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) real-time reverse transcription-PCR (rRT-PCR) testing capacities and results. SARS-CoV-2 rRT-PCR testing data were collected from 97 clinical laboratories, including 84 medical institutions and 13 independent clinical laboratories in Korea. We assessed the testing capacities to utilize SARS-CoV-2 rRT-PCR based on surveillance data obtained from February 7th to June 4th, 2020 and evaluated positive result characteristics according to the reagents used and sample types. A total of 1,890,319 SARS-CoV-2 rRT-PCR testing were performed, 2.3% of which were positive. Strong correlations were observed between the envelope () gene and RNA-dependent RNA polymerase ()/nucleocapsid () genes threshold cycle (Ct) values for each reagent. No statistically significant differences in gene Ct values were observed between the paired upper and lower respiratory tract samples, except in the gene for nasopharyngeal swab and sputum samples. Our study showed that clinical laboratories in Korea have rapidly expanded their testing capacities in response to the COVID-19 outbreak, with a peak daily capacity of 34,193 tests. Rapid expansion in testing capacity is a critical component of the national response to the ongoing pandemic.
针对持续的 2019 年冠状病毒病(COVID-19)大流行,建立了一个在线实验室监测系统,以监测严重急性呼吸系统综合症冠状病毒 2(SARS-CoV-2)实时逆转录聚合酶链反应(rRT-PCR)检测能力和结果。SARS-CoV-2 rRT-PCR 检测数据来自韩国的 97 个临床实验室,包括 84 家医疗机构和 13 家独立临床实验室。我们根据 2020 年 2 月 7 日至 6 月 4 日获得的监测数据评估了基于 SARS-CoV-2 rRT-PCR 的检测能力,并根据所用试剂和样本类型评估了阳性结果特征。总共进行了 1,890,319 次 SARS-CoV-2 rRT-PCR 检测,其中 2.3%为阳性。每个试剂的包膜()基因和 RNA 依赖性 RNA 聚合酶()/核衣壳()基因的阈值循环(Ct)值之间存在很强的相关性。除了鼻咽拭子和痰液样本的 基因外,配对的上呼吸道和下呼吸道样本的基因 Ct 值之间没有统计学上的显著差异。我们的研究表明,韩国的临床实验室迅速扩大了检测能力,以应对 COVID-19 爆发,每日最高检测能力达到 34,193 次。检测能力的快速扩大是应对当前大流行的国家应对措施的关键组成部分。